ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

MYL Mylan NV

15.855
0.00 (0.00%)
26 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Mylan NV NASDAQ:MYL NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 15.855 15.71 15.90 0 01:00:00

INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Mylan NV Investors Concerning Recent Reve...

09/11/2016 3:30pm

Business Wire


Mylan NV (NASDAQ:MYL)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Mylan NV Charts.

Law Offices of Howard G. Smith announces an investigation on behalf of investors of Mylan NV (“Mylan”) or the “Company”) (NASDAQ: MYL) concerning recent reports that the Company has unlawfully colluded with other pharmaceutical companies to fix generic drug prices.

According to news reports United States prosecutors may file criminal charges against Mylan by the end of 2016 for suspected price collusion.

Bloomberg News has reported that the “antitrust investigation by the Justice Department, begun about two years ago, now spans more than a dozen companies and about two dozen drugs, according to people familiar with the matter. The grand jury probe is examining whether some executives agreed with one another to raise prices, and the first charges could emerge by the end of the year, they said.”

The companies identified as targets or relevant parties in the United States investigation include Mylan NV, Teva Pharmaceutical Industries Ltd, Allergan Plc, Lannett Co., Impax Laboratories Inc., Sun Pharmaceutical Industries Ltd., Mayne Pharma Group Ltd., Endo International Plc and Taro Pharmaceutical Industries Ltd.

On this news, Mylan stock fell $2.53 per share, or nearly 7%, to close at $34.14 per share on November 3, 2016.

If you purchased Mylan securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at http://www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Law Offices of Howard G. SmithHoward G. Smith, Esquire215-638-4847888-638-4847howardsmith@howardsmithlaw.comwww.howardsmithlaw.com

1 Year Mylan NV Chart

1 Year Mylan NV Chart

1 Month Mylan NV Chart

1 Month Mylan NV Chart

Your Recent History

Delayed Upgrade Clock